(Q54588857)

English

A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21594619

A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. (English)

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21594619

0 references

1 reference

ChEBI release 2020-05-28

pancreatic cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21594619

author name string

Constanta Timcheva

2

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21594619

David Robert Spigel

3

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21594619

Phillip Joseph La Stella

4

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21594619

Tudor Eliade Ciuleanu

5

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21594619

G Pover

6

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21594619

N C Tebbutt

7

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21594619

publication date

19 May 2011

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21594619

Investigational New Drugs

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21594619

30

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21594619

1216-1223

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21594619

3

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21594619

https://scigraph.springernature.com/pub.10.1007/s10637-011-9687-4

0 references

Estimates of the cancer incidence and mortality in Europe in 2006.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9687-4

21 January 2018

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9687-4

21 January 2018

Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9687-4

21 January 2018

Clinical experience of MEK inhibitors in cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9687-4

21 January 2018

Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9687-4

21 January 2018

KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9687-4

21 January 2018

Recent advances of MEK inhibitors and their clinical progress

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9687-4

21 January 2018

Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9687-4

21 January 2018

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9687-4

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9687-4

21 January 2018

Design issues of randomized phase II trials and a proposal for phase II screening trials

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9687-4

21 January 2018

Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9687-4

21 January 2018

Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9687-4

21 January 2018

Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9687-4

21 January 2018

Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9687-4

21 January 2018

Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9687-4

21 January 2018

Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9687-4

21 January 2018

Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9687-4

21 January 2018

Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9687-4

21 January 2018

Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9687-4

21 January 2018

Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9687-4

21 January 2018

Second-line therapy in refractory pancreatic cancer. results of a phase II study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9687-4

21 January 2018

Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9687-4

21 January 2018

Phase II study of docetaxel and gefitinib as second-line therapy in gemcitabine pretreated patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9687-4

21 January 2018

A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21594619

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: a multicenter phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21594619

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Novel targets in solid tumors: MEK inhibitors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21594619

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice

1 reference

https://pubmed.ncbi.nlm.nih.gov/21594619

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Back to basics: explaining sample size in outcome trials, are statisticians doing a thorough job?

1 reference

https://pubmed.ncbi.nlm.nih.gov/21594619

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-011-9687-4

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21594619

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21594619

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54588857&oldid=1570029290"